In the Phase III results presented and published today, olezarsen demonstrated rapid, substantial and significant reductions in triglycerides by up to 72% on top of standard of care and reduced the ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Q3 2025 Earnings Call Transcript November 4, 2025 Verastem, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, ...
The oncology adjuvants market is expanding due to rising cancer rates, personalized medicine demand, and advances in ...
It may shock outsiders, but for Delhiites this is an annual recurrence. The air is thick with smog, and breathing it is a daily torment. What would be declared a medical emergency in many countries ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
IRDAI cautioned Universal Sompo for claim closures, refund delays, and late settlements. The insurer was warned to improve compliance and ...
According to data from the Gauteng Department of Health, between 1 January and 31 October 2025, a total of 48 typhoid fever cases were documented in the Tshwane district.
The Speaker of Parliament, Alban Bagbin, has formally apologised to the Judiciary for the heated exchanges that marred the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback